Hennion & Walsh Asset Management Inc. Purchases 5,123 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)

Hennion & Walsh Asset Management Inc. raised its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) by 14.4% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 40,790 shares of the company’s stock after acquiring an additional 5,123 shares during the quarter. Hennion & Walsh Asset Management Inc. owned approximately 0.05% of Travere Therapeutics worth $314,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Arizona State Retirement System boosted its position in Travere Therapeutics by 9.7% during the 4th quarter. Arizona State Retirement System now owns 20,969 shares of the company’s stock valued at $189,000 after acquiring an additional 1,851 shares in the last quarter. Signaturefd LLC lifted its holdings in shares of Travere Therapeutics by 1,656.4% during the fourth quarter. Signaturefd LLC now owns 3,021 shares of the company’s stock valued at $27,000 after purchasing an additional 2,849 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Travere Therapeutics by 7.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 46,424 shares of the company’s stock valued at $417,000 after purchasing an additional 3,083 shares during the last quarter. E Fund Management Co. Ltd. lifted its holdings in shares of Travere Therapeutics by 23.2% during the fourth quarter. E Fund Management Co. Ltd. now owns 22,910 shares of the company’s stock valued at $206,000 after purchasing an additional 4,314 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of Travere Therapeutics by 968.1% during the fourth quarter. Nisa Investment Advisors LLC now owns 5,650 shares of the company’s stock valued at $51,000 after purchasing an additional 5,121 shares during the last quarter.

Travere Therapeutics Price Performance

Shares of TVTX opened at $7.94 on Friday. Travere Therapeutics, Inc. has a 1-year low of $5.12 and a 1-year high of $17.57. The firm has a fifty day simple moving average of $6.97 and a two-hundred day simple moving average of $7.70. The company has a current ratio of 2.78, a quick ratio of 2.75 and a debt-to-equity ratio of 5.10. The firm has a market cap of $604.47 million, a PE ratio of -3.78 and a beta of 0.77.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings data on Monday, May 6th. The company reported ($1.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.78). Travere Therapeutics had a negative net margin of 87.94% and a negative return on equity of 238.06%. The business had revenue of $41.40 million for the quarter, compared to the consensus estimate of $43.46 million. During the same period in the previous year, the firm earned ($1.27) EPS. The company’s revenue was up 34.0% on a year-over-year basis. On average, equities analysts anticipate that Travere Therapeutics, Inc. will post -3.92 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $19.00 target price on shares of Travere Therapeutics in a report on Tuesday, May 7th. Wedbush restated an “outperform” rating and issued a $13.00 price objective on shares of Travere Therapeutics in a report on Wednesday, April 17th. Guggenheim restated a “neutral” rating on shares of Travere Therapeutics in a report on Wednesday, March 27th. Finally, Canaccord Genuity Group boosted their price objective on shares of Travere Therapeutics from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th. Five investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $15.58.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.